Sector Landscapes: Tissue & Biologics by Medical Alley Association

SECTORLANDSCAPES

TISSUE & BIOLOGICS

2015

Leading the conversation

About Sector Landscapes Publications The Sector Landscapes provide in depth analysis of emerging and established industry sectors in Minnesota. The reports highlight global industry insights, Minnesota core and supporting assets, unique positioning, company lists, and industry trends. Identified sector areas include: neuromodulation, cardiac active implantables, tissue based products, research tools, animal health, diagnostics, vascular technologies, and digital health.

List of Contributors PLEASE DIRECT CORRESPONDENCE TO:

Cheryl Matter, PhD, Vice President of Intelligence & Research, LifeScience Alley cmatter@lifesciencealley.org | 952.746.3817 Bridget Wallm, PhD, LifeScience Alley Consultant Contributing Author Elly Liao, PhD, University of Minnesota Postdoctoral Fellow Research Lead Amanda K. Weber, LifeScience Alley Design Consultant Visualization + Design LifeScience Alley's intelligence and research work is generously supported by our Foundational and Sustaining Members.

Foundational Members

Sustaining Members

About LifeScience Alley LifeScience Alley is a global leader in enabling health technology and care organizations to innovate, succeed, and influence the evolution of healthcare. By influencing policy, delivering actionable information and intelligence and connecting members with critical resources, we work to ensure that Minnesota's Medical Alley remains the world's strongest health technology community.

EXECUTIVE SUMMARY Tissue & Biologics is a rapidly growing sector in the thriving regenerative medicine industry. Historically, Minnesota has been a pioneer in tissue-based products and biologics. In fact, the first pre-market approvals issued in the state were to Coloplast and Synovis Surgical Innovations for vocal cord augmentation and vascular reconstruction respectively. There has been continued growth in the sector since the 1970s, which has led to a burgeoning cluster of biologics companies developing novel therapies using cell or tissue-based approaches to repair or replace organs and tissues.

the investment community. In 2014, life science investment in the region set a five-year high; investments in both pharma and biotech companies increased ten-fold over 2013 levels.

CUMULATIVE GROWTH OF INDUSTRY IN MINNESOTA one line = one company

Using core community competencies in cardiovascular diseases, unique tissue and biomaterial processing technologies, and tissue transplantation capabilities; the Tissue & Biologics sector in Minnesota is developing unique products that are advancing the field of regenerative medicine.

1895

The companies in this industry are succeeding by taking advantage of the strong ecosystem created by the medical device companies, supportive infrastructure at the University of Minnesota and Mayo Clinic and a highly educated workforce with a history of innovation. The primarily small companies and startups in this industry have been able to garner support from

1955

1925

1985

2014

[1] INSIDE THE TISSUE & BIOLOGICS INDUSTRY

Minnesota’s Tissue & Biologics sector is developing unique products that are advancing the field of regenerative medicine by using core community competencies in cardiovascular diseases, unique biomaterial & tissue processing technologies, and tissue transplantation capabilities. MINNESOTA INDUSTRY BY SECTOR

[2] THE GLOBAL - LOCAL COMPARISON

Of all the companies representing the Tissue & Biologics industry across the world, more than ten-percent are based out of Minnesota. GLOBAL INDUSTRY

[3] CORE CAPABILITIES IN MINNESOTA

The Therapeutics Sector and Support & Services Sector are among the most developed of the four represented core capabilities in Minnesota. THERAPEUTICS

+ Orthopedics

+ Scaffold & Matrix

+ Emerging Technologies

+ Cardiovascular Disease

BIOBANKS

TOOLS & DIAGNOSTICS

SUPPORT & SERVICES

[4] TISSUE & BIOLOGICS RESOURCE DIRECTORY

APPENDIX: LISTING OF RECENT ACQUISITIONS

LIST OF FIGURES FIGURE 1.

Breakdown Of MN Tissue & Biologics Sector by Specialty

FIGURE 2.

Global Breakdown of Sectors

FIGURE 3.

Global Companies with Tissue & Biologics Products on Market

FIGURE 4.

Cumulative Growth Of Industry Segments In Minnesota

FIGURE 5.

Breakdown of Therapeutics Sector in Minnesota

1. INSIDE THE TISSUE & BIOLOGICS SECTOR

Sector Landscapes: Tissue & Biologics | Text

114 Minnesota companies are dedicated to discovering new ways to innovate across the Tissue & Biologics sector. The regenerative medicine industry has caused a paradigm shift in healthcare therapies. Scientific advances and discoveries have allowed the shift from traditional methods that treat the symptoms of the disease to a focus on ameliorating the underlying causes of the disease. Some of the factors driving this change are: the growing elderly population which is putting a strain on the healthcare industry; increase in chronic diseases like diabetes, obesity and neurodegenerative diseases; change in reimbursement policies; and the increasing prevalence of private insurance which is willing to pay for these new treatments. This brief focuses on tissue-based products and cellular biologics, which are large sectors within the regenerative medicine industry. There is a significant potential to resolve many unmet medical needs using cell or tissue-based therapies and natural and synthetic scaffolds to replace, repair or aid in the regeneration of organs and tissues.

Sector Landscapes: Tissue & Biologics | Inside the Tissue & Biologics Sector

FIGURE 1. BREAKDOWN OF MN TISSUE & BIOLOGICS SECTOR BY SPECIALTY

114 MINNESOTA COMPANIES IN TISSUE & BIOLOGICS SECTOR

37%

08% 23%

32%

Sector Landscapes: Tissue & Biologics | Inside the Tissue & Biologics Sector

2. THE GLOBAL - LOCAL COMPARISON

Principal players in the Pharmaceutical and Biotech industry believe that the Tissue & Biologics sector is key to developing the next generation of breakthrough medicines.1 Although these companies have already invested $92 billion in research and development of cellular-based therapies, many are still actively pursuing new opportunities. Some of these investments are now coming to fruition and are generating approximately $1 billion in revenue. Since 2008, the FDA has approved six biologics products for the market.2

There are approximately 700 companies worldwide pursuing therapeutics classified as regenerative medicine therapies, 418 of which are being actively tracked by Alliance Regenerative Medicine as leading in the sector.1 In 2014, these companies acquired $2.9 billion in funding for 466 unique products and about 700 on-going preclinical and clinical trials.1 Due to this investment, the tissue biologics sector had an annual growth of 28.7% from 2008 to 2013 and is anticipated to grow 18% over the next five years.2

1 2

SOURCE: Alliance for Regenerative Medicine Annual Report 2014. SOURCE: IBISWorld Industry Report Cell Therapy, OD4040, May 2013.

Sector Landscapes: Tissue & Biologics | The Global - Local Comparison

FIGURE 2. GLOBAL BREAKDOWN OF SECTORS

12% 13%

56%

19%

FIGURE 3. GLOBAL COMPANIES WITH TISSUE & BIOLOGICS PRODUCTS ON MARKET

COMPANY & HQ LOCATION

MARKETED PRODUCT * FDA APPROVED

ANNUAL PRODUCT REVENUE APPLICATION

3M Critical & Chronic Care, Minnesota

Multiple Products

$700M

Various wound care products

Dendreon (Valeant), Washington

* Provenge™

$320M

Vaccine for prostate cancer

Organogenesis, Massachusetts

Dermagraft™, Apligraf™, * Gintuit™

$310M

Skin grafts / wound healing Gum-line restoration

Baxter International, Illinois (presence in MN)

TISSEEL™, FLOSEAL™

$162M

Medical adhesives / sealants

NuVasive, California

Osteocel™

$74M

Osteochondral defects

Aastrom, Massachusetts

* Carticel™

$35.2M

Chondral defects

Fibrocell Technologies, Pennsylvania

* LAVIV™

$0.1M

Wrinkles in nasolabial folds

Sanofi Pasteur Limited, France

* Theracys™

Bladder cancer vaccine

Multiple Centers

* HPC Cord Blood

Bone marrow transplantation

Sector Landscapes: Tissue & Biologics | The Global - Local Comparison

3. CORE CAPABILITIES IN MINNESOTA

Sector Landscapes: Tissue & Biologics | Text

THERAPEUTICS

The Tissue & Biologics sector in Minnesota has been a leader of innovative Tissue & Biologics products since the first premarket approvals (PMA) were issued for the state. In 1972, Coloplast was granted a PMA for Polytef Injection for Vocal Cord Augmentation. Synovis Surgical Innovations was granted a PMA in 1979 for a vein biograft derived from umbilical cords. The industry has continued to progress, and as a result there are currently 114 companies and organizations in Minnesota that are developing tissuebased products and cellular biologics. These companies are distributed across four sectors, some contributing to more than one sector:3

+ Therapeutics | 37 companies + Biobanks | 28 establishments + Tools & Diagnostics | 9 companies + Support & Services | 43 companies These companies secured approximately $80 million in funding in 2014. Most of the funding came from venture capital firms, but locally sponsored programs from DEED, like the Angel Investor Tax Credit, R&D Tax Credit and other business financing initiatives have also helped attract capital. Furthermore, there have been many acquisitions by larger biotechnology firms in this sector, such as the Wright Medical merger with Tornier in 2014 and the Baxter International acquisition of Synovis Surgical Innovations in 2011.4

3 4

See Tissue & Biologics Company Directory for list of MN Companies and their products within each category (p 27). See Appendix I for list of aquisitions (p 39).

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

FIGURE 4. CUMULATIVE GROWTH OF INDUSTRY SEGMENTS IN MINNESOTA THERAPEUTICS BIOBANKS TOOLS & DIAGNOSTICS SUPPORT & SERVICES forty existing companies

thirty existing companies

twenty existing companies

ten existing companies

1865

1880

1895

1910

1925

1940

1955

1970

1985

2000

Sector Landscapes: Tissue & Biologics | Text

2015 9

FIGURE 5. BREAKDOWN OF THERAPEUTICS SECTOR IN MINNESOTA5

Emerging Technologies

Scaffold & Matrix

Technological advances in stem cell research and immunotherapy are steadily becoming more prevalent among eleven companies in the Therapeutics Sector.

eleven c om pa

es ni

co m p a nies

es ni

fourteen c om pa

Fourteen Minnesota companies have been reacting to demand for biodegradable scaffold matrices, keeping them ahead in national comparisons.

fif t

co m p a ni es

Cardiovascular

Orthopedics The field of Orthopedics is one of the most established areas of technological expertise in the Minnesota region, comprised of fifteen companies.

een

With internationally-recognized cardiovascular research centers, the Tissue & Biologics sector has been able to collaborate with strong MN assets, creating nine companies.

See Tissue & Biologics Resource Directory for list of MN Companies and their products within each category (p 27).

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

THERAPEUTICS // ORTHOPEDICS Therapeutics in the orthopedics field (bone and cartilage defects) is one of the most established sectors in regenerative medicine, comprising approximately 30% of the products on the global market.6 There is also a strong presence of orthopedic companies in Minnesota, accounting for over a third of all companies in the Therapeutics sector. Many of the emerging companies in the orthopedic space are utilizing the technical expertise of the device manufacturers in the region to develop minimally invasive approaches to treat orthopedic defects.

Medtronic, Spine

Baxter Intl.

Zyga Tech.

Rotation Medical

EMERGING

Lifecore Biomedical PL

KEY

AY PL

EMERGING PLAYERS

KEY PLAYERS

Tornier/Wright Medical

Nordson Micromedics

Signus Medical

AY E RS

Liventa Bioscience

Conventus Orthopedics

Medtronic Spine Division generates $3 million annually with numerous products such as biologic infusion systems and minimally invasive surgical technologies. Tornier/Wright Biologics has many osteoconductive scaffolds and also resorbable scaffolds to be used in conjunction with biologics. Tornier recently merged with Wright Medical to form a $3.3 billion ortho-biologics company.

Rotation Medical is developing a minimally invasive, bio-inductive implant for rotator cuff repair using a novel arthroscopic delivery system. Zyga Technologies is also developing a minimally invasive procedure for sacroiliac spine fusion.

SOURCE: Alliance for Regenerative Medicine Annual Report 2014.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

THERAPEUTICS // SCAFFOLD & MATRIX Scaffolds and matrices made from natural or synthetic biomaterials have wide applications from wound healing to fixation of tissue, for hernias to the replacement of whole organs. Wound healing products, such as biological dressings and active wound care products, are another wellestablished segment of the market. The largest percentage (~38%) of all approved marketed products are for dermatological purposes.6 In addition to wound healing products, some of these companies also manufacture medical adhesives and sealants made from natural or synthetic materials for surgical operations, dental reconstruction, and orthopedic fixation. Furthermore, technology for the development of biodegradable scaffolds and biomaterials has evolved in the last decade resulting in applications beyond wound healing and surgical adhesives. Due to shortages in donor tissue or complications with donor and recipient histocompatibility, the need for natural or synthetic scaffold matrices has expanded. Many emerging companies in Minnesota are developing new processing technologies for producing unique natural scaffolds and biomaterials. In the future, these new technologies may revolutionize the regenerative medicine space by reducing the need for donor tissue.

A great resource in the orthopedic field is Excelen, Center for Bone and Joint Research and Education. It is a non-profit orthopedic research and training facility located in Minneapolis with 10,000 square feet of space dedicated for developing innovative surgical and rehabilitative techniques. The facilities include the surgical skills lab for training or testing new protocols and a biomechanics lab with the ability to test cadaveric biomechanics.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

THERAPEUTICS // SCAFFOLD & MATRIX Tornier/Wright Medical Admedus Gel-Del Technologies

KEY PLAYERS EMERGING PLAYERS 7

NATURAL

Liventa Bioscience

Coloplast

Kips Bay Medical

BRTI Life Sciences

Rotation Medical Baxter Intl. Miromatrix

Signus Medical

ATER IAL

Endo Pharma AMS, Inc.

3M, Critical and Chronic Care Division holds 12% global market share of both wound healing and medical adhesive products ($700 million annually).7 Baxter International holds 9.4% global market share in medical adhesives ($163 million annually).7 Coloplast has both natural and synthetic wound healing products, as well as naturally derived products for urologic indications and surgical procedures.

Miromatrixâ&#x20AC;&#x2122;s tissue decellularization technology produces a natural tissue scaffold that currently is used for treatment of hernias, but the decellularization process is transferrable to whole organs. Miromatrix is working with Mayo Clinic to develop a decellularized whole liver transplant. Admedusâ&#x20AC;&#x2122; cardiocel technology uses a decellularized bovine graft for congenital heart defects and other complex cardiovascular defects. Liventa Bioscience develops novel products for both wound dressing and orthopedic use from placental tissue and amniotic fluid.

SOURCE: IBISWorld Industry Report Wound Care Product Manufacturing, OD4099, April 2014 and IBISWorld Industry Report Medical Adhesives & Sealants Manufacturing, OD4095, June 2014.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

THERAPEUTICS // EMERGING TECHNOLOGIES Approximately a quarter of Minnesota companies in the Tissue & Biologics space are working on emerging technologies. These companies can be categorized into three groups: + Cell-based immunotherapy is the youngest category in regenerative medicine,

but it is one of the hottest areas in regenerative medicine. These companies produce a variety of immune products from interleukins, antibodies, lymphocytes, T-cells, and natural killer cells.8 Most of the companies are using the bodyâ&#x20AC;&#x2122;s own immune cells to target various forms of cancer.

+ Stem cell and progenitor therapies are the largest category in regenerative medicine. These therapies have garnered the most investment and have the greatest potential to produce breakthrough therapeutics for the regeneration of tissues and treatment of diseases.8

+ Other novel technologies include products for optometric purposes and new biologic drugs.

BioE CytoMedical Design Group

Altravax Omnis Pharmaceuticals

Rebiotix

M IM

EM ST

Lifecore Biomedical

IES RAP E TH LL E C Liver Cell Therapies

APY

H ER

Silk Tears

Cardio3 Biosciences (Celyad Subsidiary) BioMatRx Biothera

Biovest Intl.

SOURCE: Alliance for Regenerative Medicine Annual Report 2014.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

THERAPEUTICS // EMERGING TECHNOLOGIES

EMERGING PLAYERS

Biovest International is leading the field of personalized medicines by creating vaccines targeting non-Hodgkinâ&#x20AC;&#x2122;s lymphoma using the patientâ&#x20AC;&#x2122;s own immune cells. Omnis Pharmaceuticals recently received a licensing agreement with MedImmune / AstraZeneca for its genetically engineered virus targeting cancer cells. BioMatRx is developing a root canal alternative using dental pulp stem cells and a mixture of growth factors to stimulate new growth. Liver Cell Therapies is constructing an artificial liver bioreactor using pig islets. Rebiotix is generating a first-in-class biologic drug using live human-derived organisms to treat Clostridium difficile infections. They are currently testing the novel microbiota suspension in Phase 2 clinical trials.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

THERAPEUTICS // CARDIOVASCULAR Minnesota is a pioneer in open heart surgery and continues to be a leader in cardiovascular disease management. The heavy concentration of medical device companies and the presence of the Lillehei Heart Institute form a large knowledge base around the cardiovascular sciences. By combining tissue engineering principles with this technical expertise in cardiology, these companies have expanded beyond heart valve implants and are developing the next generation of cardiovascular products. Baxter Intl. (Synovis Surgical) Heart Leaflet Technologies

Cardio3 Biosciences (Celyad Subsidiary) Gel-Del Technologies

HEART VA LVES

EMERGING PLAYERS

St. Jude Medical

NEW T E C H N O

TissX Tendyne Holdings

LOG

IE S

Kips Bay Medical Admedus

Heart Leaflet Technologies has a transcatheter delivery system for a porcine heart valve with mesh support system. Tendyne (recent acquisition by Abbott Laboratories) developed a mitral valve replacement using a transcatheter delivery system without the need for coronary bypass. Cardio3 Biosciences (Celyad Subsidiary) is collaborating with the Mayo Clinic to use cardiopoietic stem cells for treating patients with congestive heart failure. They received FDA approval to start Phase III trials in late 2014.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

BIOBANKS With the first successful allogeneic bone marrow transplantation in 1968, Minnesota has been a leader in tissue and organ transplantation, and continues to advance the field of transplantation research. Both the University of Minnesota Medical Center and the Mayo Clinic in Rochester are consistently ranked among the â&#x20AC;&#x153;Top Hospitalsâ&#x20AC;? in the nation by U.S. News and World Report. In fact the Mayo Clinic, Rochester, was ranked the Number One hospital in 2014 due to its fifteen top-ranked adult specialties and nine pediatric programs.9 U of M, Liver Tissue Cell Distribution System Minnesota

American Red Cross

B BI O

Lions American Donor Services Eye Bank

KS AN LifeSource

Mayo Clinic, Bipolar Disorder Biobank

Hennepin County Medical Center

Cyrogenic Laboratories

SPI

TAL S

Mayo Clinic U of M Medical Center

Musculoskeletal Transplant Foundation National Marrow Donor Program

Mayo Clinic, Mitochondrial Disease Biobank

Regions Hospital

LifeStor Cordblood Services

SOURCE: U.S. News and World Report Best Hospitals 2014 - 2015 Honor Roll.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

BIOBANKS

KEY PLAYERS

National Marrow Donor Program (NMDP) is a nonprofit organization that manages the largest and most diverse bone marrow registry in the world. NMDP is also an expert in bioinformatics. American Donor Services is a nonprofit organization that facilitates tissue donations and it will be one of the first organizations in the area with the capability to process human tissue. Minnesota Lions Eye Bank is one of the largest eye banks in the world and has contributed many innovations in corneal preservation and transplantation research. Mayo Clinic, Rochester is not only one of the top hospitals in the nation, but also has three biobanks for scientific research. University of Minnesota Medical Center has the second largest unrelateddonor transplant program in the nation and one of the largest umbilical cord transplant centers worldwide, due to collaboration with NMDP. The University of Minnesota also has many institutes and biobanks that rely on UMMC to support scientific research and collaboration.

The National Marrow Donor Program (NMDP) is headquartered in Minneapolis and has the largest hematopoietic registry in the nation with over 10 million donors and 185,000 cord blood units. The NMDP helps coordinate over 6000 donor-recipient transplants per year. It also holds the highest number of biologics license applications (BLA) and investigational new drug (IND) applications in the region. Furthermore, the NMDP has advanced knowledge of complex histocompatibility algorithms and is vested in advancing the field of bioinformatics. NMDP, along with the University of Minnesota Rochester, the Hormel Institute, the University of Minnesota Twin Cities, the Mayo Clinic, IBM, and Cray Inc., launched the Biomedical Informatics and Computational Biology Program. The vision of this bioinformatics research program is to advance translational medicine by applying immunobiology, histocompatibility, and population genetics. NMDP collaborates with the Medical College of Wisconsin to fund the Center for International Blood and Transplant Research (CIBTR). The purpose of CIBTR is to enhance collaborations with the global scientific community to advance hematopoietic cell transplantation and cellular therapy research.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

TOOLS & DIAGNOSTICS Minnesota also has a significant presence in the tools and diagnostics field with several large players headquartered in the area.10 A small number of the small and/or emerging companies in this space are working specifically on cell-based assays for drug or toxicity screening, and creative technology platforms for processing tissue products. Imanis Life Sciences

StemoniX

Circle Biologics

CellPro Labs

TOOLS

Altravax

DIA G N O S

Nordson Micromedics

BioE -CytoMedical Design Group

Mill Creek Life Sciences

TIC S

Celcuity

EMERGING PLAYERS

Circle Biologics developed a device for sorting and collecting blood and peripheral cells. BioE -CytoMedical Design Group has a FDA approved system for improved cord blood processing and multi-lineage progenitor cells available for diagnostics. StemoniX is creating low-cost drug discovery assay plates using regenerative medicine. CellPro Labs has both cell lines and cell culture products for viral diagnosis and detection.

See LifeScience Alley's Diagnostics Capability Brief

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

SUPPORT & SERVICES The Tissue & Biologics companies in Minnesota are surrounded by a strong network of supporting organizations. While there is a strong academic presence in the Mayo Clinic and the University of Minnesota, private sector companies in Minnesota also have much to offer, from early stage research through post-market support. These 43 companies are distributed among four different categories, some contributing to more than one category. + + + +

Contract manufacturing and development (15) Clinical/quality/regulatory (13) Logistics/distribution (8) Support/testing (22)

Taking a product from a mere idea all the way to the clinic is a challenge that Minnesota companies are skilled at addressing. SUPPORT & SERVICES: ACADEMIC & INSTITUTIONAL RESOURCES Much of the support infrastructure can be found at the University of Minnesota or the Mayo Clinic. Both have strong research laboratories with expertise in biotechnology, core research facilities with state of the art equipment and incubator space for startups. They also have initiatives that help startups and emerging companies create business models based on the Lean Development methodology. Mayo Clinic In 2006, Mayo Clinic was one of twelve institutions awarded with a Clinical and Translational Science Award from the National Institutes of Health. This funding provides support for the Center for Clinical and Translational Science (CCaTS), the largest research-related center at Mayo Clinic. CCaTS administrates the support infrastructure for clinical research, patient-oriented research and other development programs that enable the acceleration of translating laboratory discoveries into improved patient care. Due to programs like the Center for Clinical and Translational Science, Mayo Clinic has been particularly successful at the development of translational research for clinical applications. Mayo Clinic also has a few business resources for licensing technology and fostering startups: Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

SUPPORT & SERVICES: ACADEMIC & INSTITUTIONAL RESOURCES +

Mayo Clinic Ventures is helping to bridge science technologies with the marketplace. Mayo Clinic currently has over 2,000 technologies available for licensing. They have been involved in the creation of 65 startup companies and over 2,600 licensing deals since inception.

Mayo Clinic Business Accelerator is a 2,000 square-foot facility that provides collaborative office space for new companies, entrepreneurs and venture capital firms. As a joint venture between Mayo Clinic Ventures, the Rochester Area Economic Development, Inc. and Mayo Clinic Treasury Services, it currently has twenty tenants with plans for expansion in 2015.

University of Minnesota The University of Minnesota offers many additional resources and facilities, and is part of the greater consortium of the 62 Clinical and Translational Science Award (CTSA) institutions. CTSA institutions are committed to the improvement of â&#x20AC;&#x153;human health by streamlining science, transforming training environments and improving the conduct, quality and dissemination of clinical and translational research.â&#x20AC;? Listed below are the several existing research and service facilities for biotechnology and life sciences at the University of Minnesota. + + + + + + + + +

Imaging Center Biotechnology Resource Center Center for Mass Spectrometry and Proteomics Flow Cytometry Core Genomics Center Molecular Cellular Therapeutics (MCT; see inset for more information) Masonic Cancer Center Schulze Diabetes Institute Office for Technology Commercialization (OTC)

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

MOLECULAR & CELLULAR THERAPEUTICS

Molecular and Cellular Therapeutics (MCT) is a 36,000 square foot Good Manufacturing Practices (GMP) facility on the University of Minnesota, Twin Cities campus. The focus of MCT is on translational development and clinical production of biologics for human use by facilitating the scale-up of products that have gone through the proof of concept stage for Phase I and II clinical trials. It is one of the few stand-alone GMP manufacturing facilities in the nation and one of five sites in the US that was awarded with a Production Assistance for Cellular Therapeutics (PACT) grant from the National Heart, Blood and Lung Institute. The purpose of the PACT grant is to assist the translational research of cellular therapeutics and support the manufacture of novel cellular therapeutic products. MCT has a strategic development process for bio-therapeutics, which consists of a five phase Product Development Process, an independent cGMP / cGTP Quality Assurance Program, and routine Risk Management Analysis Unit. Currently MCT has dedicated spaces for six programs: Cancer Center Translational Laboratory, UMMC Cell Therapy Laboratory, Schulze Diabetes Institute, Fecal Microbiota Transplant, Targeted Toxins, and Institute for Therapeutics Discovery & Development. In addition to this space, MCT also has clean room production suites available for short-term or temporary programs.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

SUPPORT & SERVICES: PRIVATE SECTOR SERVICE PROVIDERS As exhibited by the wide variety of companies that provide services from idea development to early stage manufacturing to regulatory testing to funding sources, private Minnesota companies are able to provide many services that complement those offered by research institutions. Several companies in the service sector are profiled below: NACS began as a production development company in 1991, and has since transitioned into contract manufacturing and development for the life sciences. With approximately 180 projects per year, their FDAcertified facility with clean rooms is geared to assist companies from idea to global launch and everything in between. In particular, they have expertise in GMPs for North America, Europe and Asia. They also specialize in helping companies find innovative funding sources for new products in their pipeline. NAMSA began in 1967 as a company focused on safety testing and microbiology services. Ten years later, they helped the FDA set up testing guidelines for medical devices, and have continued to be an expert in worldwide regulatory and quality assurance standards. Today, NAMSA not only sells sterility products, but also acts as a service organization to other companies, assisting them with research and development of products through post-market support, with expertise in all disciplines. Particularly, the recent acquisitions of the Integra Group and Alquest have added a deep level of expertise in the preclinical and clinical trial stages of product development. NAMSA has the capability to help companies at any stage of the pipeline, from biocompatibility testing to early feasibility studies to GLP studies to post market clinical trials, and also plays matchmaker between companies and potential funding sources. StemoniX produces robust heart and brain cell populations using a proprietary process of stem cell differentiation. Their process uses a suite of techniques to produce standard size microtiter plates for preclinical in vitro testing and diagnostics. While these are primarily for drug screening purposes, there is potential for many downstream applications. Despite incorporation in April of 2014, StemoniX has already progressed beyond seed stage funding to collaborations with two pharmaceutical companies. While their R&D facilities are based out of a Johnson & Johnson incubator in San Diego, manufacturing operations will begin soon in Minnesota.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

SUPPORT & SERVICES: PRIVATE SECTOR SERVICE PROVIDERS TissX, founded here in Minnesota in 2013, not only produces their own tissue-based devices, but also assists other companies in the complicated road from product development to utilization in the clinic. Their facility is FDA-compliant, and they are experienced in leveraging their robust infrastructure to assist companies from initial pre-clinical tests through production, packaging, sterilization, sales and distribution. They have experience and connections within foreign medical device markets, with knowledge of both import and export requirements for a number of countries. They have a pragmatic approach to product development, knowing that all companies have different goals and requirements for their individual products. The Seed Partners is a newly opened biosciences incubator, accelerator and investor in the North Loop. Their 27,000 square foot space includes a 5,000 square foot wet lab facility, including fume hoods, cell culture space, and other basic & specialized life science equipment. Their Seed R&D company, in addition to providing shared lab and collaborative work spaces, can assist clients from the early stages of an idea to product concept, as well as provide business support, office support and laboratory support services. Innovative Blood Resources (IBR) is widely known as a provider of human cells and tissues for use in research, manufacturing, product development and design and clinical trials within the life sciences industry. Offering unparalleled consulting expertise, IBR assists companies in navigating the complex world of regulatory and quality control to achieve FDA approval. IBR has widespread experience in maintaining programs requiring human subjects and cGMP compliance, and their FDA-certified facility provides lab space for testing during pre-clinical and clinical trials. Additionally, they have an efficient infrastructure for storing, shipping and handling biologics. Dohmen Life Science Services provides outsourced insight and infrastructure to entrepreneurs seeking speed, scale and certainty as they bring their biopharma or medical device products to market. Dohmen's industry experts help hundreds of companies preserve capital, mitigate risk and stay focused on the future by supplying exceptional people, processes and tools within the areas of finance, technology, quality, regulatory compliance, supply chain, customer services and patient support.

Sector Landscapes: Tissue & Biologics | Core Capabilities in Minnesota

IN CONCLUSION The Tissue & Biologics sector in Minnesota is a rapidly growing field with a repertoire of a few established key players and an extensive array of small companies working on new emerging technologies. First, the University of Minnesota and the Mayo Clinic not only provide a highly educated workforce, but also world class research facilities and resources. Second, Minnesota has a substantial presence of key opinion and thought leaders in core capabilities such as cardiovascular disease, tissue and organ transplantation and biomaterial technologies. Finally, the diverse private companies that are able to assist in technology development from idea to post-market support lower the cost of operations and expansion, especially when compared to other cities in the nation. Overall, Minnesota continues to foster an environment that allows for businesses to advance the rapidly changing field of regenerative medicine.

Sector Landscapes: Tissue & Biologics | Conclusion

4. TISSUE & BIOLOGICS RESOURCE DIRECTORY

Sector Landscapes: Tissue & Biologics | Text

THERAPEUTICS: ORTHOPEDICS Company

City, State

Founded Summary

Baxter International, Inc. Synovis Surgical Innovations

St. Paul, MN

1985

ACTIFUSE bone grafts, soft tissue repair, microsurgery products.

Conventus Orthopedics

Maple Grove, MN

2008

Fixation of distal radius fractures using nitinol mesh system.

Liventa Bioscience

Woodbury, MN

2006

Placenta-derived graft for wound care and amnionic fluid for orthopedic applications.

Lifecore Biomedical LLC (part of Landec)

Chaska, MN

1986

Manufactures Hyaluronan and other biomaterials for various medical applications.

Medtronic, Spine & Biologics Business

Minneapolis, MN

1949

Infuse bone graft for spinal, maxilofacial, and tibial bone growth.

Nordson Micromedics

St. Paul, MN

1982

Bone graft, fibrin gel injection delivery systems. CDO capabilities.

Rotation Medical

Plymouth, MNÂ

2009

Bioinductive implant (collagen) for formation of new tendonous tissue for rotator cuff tears.

Signus Medical LLC

Chanhassen, MN

2001

Bone conductive matrix for spine made from HA/TCP (hydroxyapatite/tricalcium phosphate).

Smith & Nephew

Bloomington, MN

1856

Various orthopedic products.

SOTA Inc.

Eden Prairie, MN

1990

Distributor of bone graft products.

Stellen Medical

St. Paul, MN

Manufacturer of porcine xenografts

Tornier Biologics (Wright Medical merger)

Bloomington, MN

1930

Many osteoconductive matrices in biologics division; develops synthetic, resorbable scaffolds.

Zyga Technology, Inc.

Minnetonka, MN

2008

Sacroiliac spine fusion system, delivers bone grafts.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

THERAPEUTICS: CARDIOVASCULAR Company

City, State

Founded Summary

Admedus

Minneapolis, MN

2013

Decellularized bovine pericardium using ADAPT technology.

Baxter International, Inc. Synovis Surgical Innovations

St. Paul, MN

1985

ACTIFUSE bone grafts, soft tissue repair, microsurgery products.

Gel-Del Technologies VasoLogix / Cosmeta Corp.

St. Paul, MN

2000

Blood vessel grafts made from biomaterials, HyA injections.

Cardio3 Biosciences (Celyad Subsidiary)

Mont-Saint-Guibert, 2007 Belgium

Guided cardiopoiesis using hematopoietic stem cells.

Heart Leaflet Technologies (Bracco Group)

Maple Grove, MN

2002

Transcatheter delivery of porcine valve with wire mesh support system.

Kips Bay Medical

Minneapolis, MN

2007

Mesh support for saphenous vein grafts. Improves vessel wall support.

St. Jude Medical

St. Paul, MN

1976

Heart tissue valves made from porcine leaflets.

Tendyne Holdings, Inc.

Roseville, MN

2010

Mitral valve replacement using transcatheter approach without cardio bypass.

TissX

Maple Grove, MN

Creator of cardiovascular and orthopedic tissue-based devices; contract manufacturer and product developer.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

THERAPEUTICS: SCAFFOLD & MATRIX Company

City, State

Founded Summary

3M Critical & Chronic Care

St. Paul, MN

1902

Various wound healing products and medical adhesives.

Admedus

Minneapolis, MN

2013

Decellularized bovine pericardium using ADAPT technology.

Baxter International, Inc. Synovis Surgical Innovations

St. Paul, MN

1985

ACTIFUSE bone grafts, soft tissue repair, microsurgery products.

BRTI Life Sciences

Two Harbors, MN

2013

Hyaluronic Acid / Chitosan matrix for cells.

Coloplast Corporation

Minneapolis, MN

1957

Bovine pericardium for urological procedures, Alginate and silicone for wound healing.

Endo Pharmaceuticals American Medical Systems, Minnetonka, MN Inc. (Acquired by Boston Sci)

1972

Meshes for pelvic health problems incontinence and prostate.

Gel-Del Technologies VasoLogix / Cosmeta Corp.

St. Paul, MN

2000

Blood vessel grafts made from biomaterials, HyA injections.

Impres Medical, Inc.

Minnetonka, MN

1999

Minimally invasive treatment for abnormal uterine bleeding.

Kips Bay Medical

Minneapolis, MN

2007

Mesh support for saphenous vein grafts. Improves vessel wall support.

Liventa Bioscience

Woodbury, MN

2006

Placenta-derived graft for wound care and amnionic fluid for orthopedic applications.

Miromatrix Medical, Inc.

Eden Prairie, MN

2009

Decellularized tissue / organ technology. First product was biological mesh for hernia repair.

Rotation Medical

Plymouth, MNÂ

2009

Bioinductive implant (collagen) for formation of new tendonous tissue for rotator cuff tears.

Signus Medical LLC

Chanhassen, MN

2001

Bone conductive matrix for spine made from HA/TCP (hydroxyapatite/tricalcium phosphate).

Tornier Biologics (Wright Medical merger)

Bloomington, MN

1930

Many osteoconductive matrices in biologics division; develops synthetic, resorbable scaffolds.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

THERAPEUTICS: EMERGING TECHNOLOGIES Company

City, State

Founded Summary

Altravax

Fargo, ND

2009

Vaccine development platform Immunogen Optimization System (IOS), Molecular Breeding, Parallelavax, and ParaClin systems.

BioE - CytoMedical Design Group (CMDG)

St. Paul, MN

1993

Multi-Lineage Progenitor cells derived from umbilical cords; cord blood processing technology.

BioMatRx LLC

Edina, MN

2010

Dental pulp stem cells in place of root canals.

Biothera, Inc.

Eagan, MN

1997

Cancer therapy.

Biovest International

Minneapolis, MN

1983

Vaccine for non-Hodgkin's Lymphoma; process autologous cells.

Cardio3 Biosciences (Celyad Subsidiary)

Mont-Saint-Guibert, 2007 Belgium

Guided cardiopoiesis using hematopoietic stem cells.

Lifecore Biomedical LLC (part of Landec)

Chaska, MN

1986

Manufactures Hyaluronan and other biomaterials for various medical applications.

Liver Cell Therapies

Rochestser, MN

2014

Liver bioreactor using pig islets.

Omnis Pharmaceuticals

Rochester, MN

2014

Genetically engineered virus targeting cancer cells.

Rebiotix (formerly MikrobEX Inc.)

Roseville, MN

2011

Biologic drug made of microbiota to treat human metabolic disease.

Silk Tears, Inc. (formerly Seryx Biomedical)

Maple Grove, MN

2010

Silk fibroin eye drops for ophthalmic therapies.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

BIOBANKS Company

City, State

Founded Summary

Allina Health Laboratories

Minneapolis, MN

1882

Fertility.

American Donor Services

Hastings, MN

2007

Human tissue donation organization.

American National Red Cross St. Paul, MN (The)

1863

Supplies approximately 66% of all donated blood in US.

Center for Reproductive Medicine, P.A.

Minneapolis, MN

1987

Fertility.

Cryogenic Laboratories, Inc.

Roseville, MN

1974

Fertility (sperm bank).

Hennepin County Medical Center

Minneapolis, MN

1887

Fertility.

International Assisted Reproduction Center

Maple Grove, MN

1982

Fertility.

LifeSource - Upper Midwest OPO

St. Paul, MN

1989

Human tissue donation organization.

LifeStor Cordblood Services

Roseville, MN

Umbilical cordblood.

Lions Eye Bank

St. Paul, MN

1989

Human tissue donation organization.

Mayo Clinic Biobank

Rochester, MN

2009

Collect any tissue specimens from human volunteers and medical history.

Mayo Clinic Bipolar Disorder Biobank

Rochester, MN

Large scale bipolar disorder biobank with biologic samples and clinical data.

Mayo Clinic Mitochondrial Disease Biobank

Rochester, MNÂ

2009

Collect and distribute specimens from human patients with mitochondrial diseases.

Mayo Clinic Health System Mankato

Mankato, MN

Organ transplantation.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

BIOBANKS Company

City, State

Founded Summary

Mayo Clinic Rochester

Rochester, MN

Fertility.

Mayo Clinic Rochester Division of Transfusion Medicine

Rochester, MN

Progenitor / Bone marrow transplantation.

Muscoloskeletal Transplant Foundation

Eagan, MN

2005

Human tissue donation organization.

National Marrow Donor Program

Minneapolis, MN

1986

Largest, most diverse marrow registry. Leader in bone marrow transplants.

Regions Hospital

St. Paul, MN

1872

Tissue transplantation.

Reproductive Medicine & Infertility Associates

Woodbury, MN

1998

Fertility.

ReproTech, Ltd.

St Paul, MN

1990

Fertility.

The Midwest Center for Reproductive Health, P.A.

Maple Grove, MN

1991

Fertility.

Tissue Trust

Edina, MN

Human tissue.

University of Minnesota BioNET Tissue Procurement Facility

Minneapolis, MN

1996

Collects and distributes human tissue specimens to scientific investigators.

University of Minnesota Liver Tissue Cell Distribution System

Minneapolis, MN

Collects and distributes human liver specimens to scientific investigators.

University of Minnesota Medical Center, Fairview Laboratories

Minneapolis, MN

Progenitor / Bone marrow transplantation.

University of Minnesota Medical Center, Fairview Cell Therapy

Saint Paul, MN

Progenitor / Bone marrow transplantation.

University of Minnesota Physicians

Minneapolis, MN

Fertility.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

TOOLS & DIAGNOSTICS Company

City, State

Founded Summary

Altravax

Fargo, ND

2009

Vaccine development platform Immunogen Optimization System (IOS). Molecular Breeding; Parallelavax; and ParaClin systems.

BioE - CytoMedical Design Group (CMDG)

St. Paul, MN

1993

Cord blood processing technology, lysing red blood cells, and activating T-cells.

Celcuity LLC

Minneapolis, MN

2014

Microarray using patient's cells.

CellPro Labs

Golden Valley, MN

2013

Cell lines (both primary and subcultures) for diagnostics.

Circle Biologics, Inc.

Minneapolis, MN

2008

Medical devices for collecting blood and cells.

Imanis Life Sciences

Rochester, MN

2012

Noninvasive reporter systems with cell lines, lentivectors, oncolytic viruses, and contract imaging services.

Mill Creek Life Sciences LLC

Rochester, MN

2010

Human protein based cell culture supplement derived from human donor platelets.

Nordson Micromedics

St. Paul, MN

1982

Bone graft, fibrin gel injection delivery systems. CDO capabilities.

StemoniX

Rochester, MN

2014

Provider of derived organ cell populations on standard-size microtiter plates for testing and diagnostics.

Company

City, State

Founded Summary

Airmed Biologics, Inc.

Stillwater, MN

2011

Regenerative medicine company with expertise in human and animal tissue-derived product design / development.

Biomedical Synergies

Wayzata, MN

2005

Consulting and software for tissue management.

Biotest Laboratories, Inc. (STERIS Subsidiary)

Brooklyn Park, MN

1998

CRO; testing services for pharmaceutical, medical device, and material suppliers.

SUPPORT & SERVICES

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

SUPPORT & SERVICES Company

City, State

Founded Summary

Biovest International

Minneapolis, MN

1983

Vaccine for Follicular Lymphoma. Process autologous cells.

ChRi Laboratories

St. Paul, MN

2013

CRO; early stage R&D, drug release / stability / degradation studies and regulatory submissions. Dohmen Life Science Services provides outsourced insight and infrastructure to entrepreneurs seeking speed, scale and certainty as they bring their biopharma or medical device products to market. Our industry experts help companies within the areas of finance, technology, quality, regulatory compliance, supply chain, customer services and patient support.

Dohmen Life Science Services

Milwaukee, WI

1858

Imanis Life Sciences

Rochester, MN

2012

Noninvasive reporter systems with cell lines, lentivectors, oncolytic viruses and contract imaging services.

Infinity Transplant Services, Inc.

Stillwater, MN

Medical transplant consulting firm.

Innovative Blood Resources

St. Paul, MN

2012

Clinical research support, testing services, blood and cellular products and consulting.

Innovative Surface St. Paul, MN Technologies, Inc. (ISurTec)

2004

CRO; develops scaffold/matrices, drug delivery, surface coatings, wound dressing; founded by co-Founder of Surmodics.

J. K. Medical, Inc., Consulting Services

Roseville, MN

2004

Consulting firm for product development, compliance and regulation, contract manufacturers and pricing strategies

Mayo Clinic Validation Support Services

Rochester, MN

Provides high quality, high volume tissue and biospecimen preparation and storage.

MD Biosciences, Inc. (Morwell Diagnostics Switzerland)

St. Paul, MN

1999

Preclinical CRO for inflammation, CNS, pain and cardiovascular.

MedTech Solutions North

St. Paul, MN

Medical equipment and supplies.

Medtox Laboratories, Inc.

St. Paul, MN

2005

Drug testing laboratory and clinical trial management.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

SUPPORT & SERVICES Company

City, State

Founded Summary

Midwest Research Swine - Porcine Recovery

Gibbon, MN

1986

Molecular and Cellular Therapeutics

UMN; St. Paul, MN 1992

Provides cGMP / cGTP grade materials and support. FDA approved for IND.

NACS, Inc.

Ham Lake, MN

1991

Specializes in contract manufacturing and process design for life science products.

NAMSA

Minneapolis, MN

1967

Helps clients develop medical products from concept to market along the entire development timeline.

SOTA Inc.

Eden Prairie, MN

1990

Distributor of bone graft products.

Spring Point Project

Minneapolis, MN

2004

Provider of Designated Pathogen Free pigs; clinically suitable, viable porcine tissues and cellular products.

TissX

Maple Grove, MN

2013

Develops and manufactures tissue patch and valve impants.

US Medical Technologies

Lakeville, MN

1974

Medical / dental supplies and equipment.

WuXi AppTec

St. Paul, MN

2000

CRO, medical device testing and material characterization facilities.

Laboratory

City, State

Contact

Summary

Andre Terzic, M.D., Ph.D. Laboratory/ Cardio3 Biosciences

Mayo; Rochester, MN

Andre Terzic, M.D., Ph.D.

Guided cardiopoiesis using hematopoietic stem cells.

Chun Wang Laboratory

UMN; Minneapolis, MN

Polymeric biomaterials with drug Chun Wang, Ph.D. delivery and creation of stem cell wangx504@umn.edu niches.

Michael Yaszemski, M.D., Ph.D. Laboratory

Mayo; Rochester, MN

Michael Yaszemski, Bone, cartilage and nerve tissue M.D., Ph.D. engineering using novel Yaszemski.Michael@ biomaterials and scaffolds. mayo.edu

Provides high quality traceable porcine tissue and other pigs for medical device and research purposes

RESEARCH LABORATORIES

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

RESEARCH LABORATORIES Laboratory

City, State

Contact

Summary

Peter Amadio, M.D. Laboratory

Mayo; Rochester, MN

Peter Amadio, M.D. pamadio@mayo.edu

Combined polymeric scaffolds and stem cells for tendon regeneration.

Robert T Tranquillo Laboratory

UMN; Minneapolis, MN

Robert Tranquillo, Ph.D. tranquillo@umn.edu

Cardiovascular tissue engineering.

Scott Nyberg, M.D. Ph.D.

Mayo; Rochester, MN

Scott Nyberg, M.D., Development of extracoporeal Ph.D. artificial liver support system Nyberg.Scott@mayo. (HepatAssist) edu

Research Facilities

City, State

Contact

Summary

BioCoR

UMN; Minneapolis, MN

Alison Hubble biocore@me.umn. edu

Services, research & educational resources for biopreservation for biobanking and cell therapy.

RESEARCH FACILITIES

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

RESEARCH FACILITIES Research Facilities

City, State

Contact

Summary

Biotechnology Resource Center (BRC)

UMN; St. Paul, MN

Tim Tripp tripp006@umn.edu

Fermentation, downstream processing, protein expression and GMP capabilities

https://cbs.umn.edu/ cmsp/about

Provides support, equipment and expertise for analyzing complex protein mixtures. Educates and assists orthopedic researchers as they develop and innovative surgical and rehabilitative techniques

Center for Mass UMN; Minneapolis, Spectrometry & Proteomics MN

Excelen

Minneapolis, MN

info@excelen.org

Masonic Cancer Center

UMN; Minneapolis, MN

http://www.cancer.umn. Immune monitoring assays & GMP edu/research/translational-cell-therapy/index.htm cell processing for clinical trials.

Mayo Validation Support Services

Mayo; Rochester, MN

mvss@mayo.edu

Mayo Clinic Ventures

Mayo; Rochester, MN

Link between research and mayoclinicventures@ innovations with businesses looking mayo.edu to license technology.

Mayo Clinic Business Accelerator

Mayo; Rochester, MN

xfrigola@raedi.com

Collaborative office space for startups, entrepreneurs, investors and advisors.

Molecular and Cellular Therapeutics

UMN; St. Paul, MN

Diane Kadidlo kadid003@umn.edu

Provides cGMP / cGTP grade materials and support. FDA approved for IND.

Office for Technology Commercialization

UMN; Minneapolis, MN

Jay Schrankler jwschrankler@umn. edu

Facilitates transfer of UMN research to licensees for development of products/services.

The SEED Partners

Minneapolis, MN

info@theseed partners.com

Incubator/accelerator with 27,000 sq. ft. space, includes 5,000 sq. ft. wet lab facility.

Stem Cell Institute

UMN; Minneapolis, MN

sci-admn@umn.edu

iPS facility, confocal microscopy, and flow cytometry.

University Enterprise Laboratories LLC

St. Paul, MN

Greg LaSalle info@uelmn.org

Bioscience incubator space.

University Flow Cytometry Resource

UMN; Minneapolis, MN

Paul Champoux champ004@umn.edu

Provides flow cytometry support.

University of Minnesota Genomics Center

UMN; Minneapolis, MN

http://www.health.umn. edu/research/resources-researchers/genomics-center

Genomics research & advises clients on appropriate technology.

University of Minnesota Imaging Center

UMN; Minneapolis, MN

http://uic.umn.edu/

Provides advanced imaging technologies and methodologies to UMN and external users.

Preclinical validation, diagnostics and therapeutic discoveries, and biospecimen prep and storage.

Sector Landscapes: Tissue & Biologics | Tissue & Biologics Resource Directory

APPENDIX: LISTING OF RECENT ACQUISITIONS

Sector Landscapes: Tissue & Biologics | Text

LIST OF ACQUISITIONS Company

Acquired

Amount

Year

Wright Medical

Tornier Biologics

$3.3B

2014

Zimmer

Biomet

~$845M

2014

Baxter International

Synovis Life

$325M

2011

Endo Pharmaceuticals American Medical Systems, American Medical Systems Inc. (Acquired by Boston Sci)

$2.9B

2011

Heart Leaflet Technologies

Bracco Group

undisc.

2010

Landec

Lifecore Biomedical

$40M

2010

Nordson

Micromedics

undisc.

2010

Sector Landscapes: Tissue & Biologics | Appendix